Compare Stocks → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APREOTCMKTS:EMISNASDAQ:RAPTNASDAQ:TXMDOTCMKTS:VEGPF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$6.69+10.2%$6.36$2.78▼$8.85$25.02M1.0536,149 shs28,419 shsEMISEmisphere Technologies$7.81$7.81$4.06▼$9.16N/AN/AN/AN/ARAPTRAPT Therapeutics$8.98+0.6%$16.25$6.86▼$27.35$312.50M0.471.27 million shs860,932 shsTXMDTherapeuticsMD$2.29+1.8%$2.31$1.95▼$4.72$24.23M1.0318,652 shs9,722 shsVEGPFVectura Group$1.77$1.77$1.64▼$2.74$1.07B0.372,185 shsN/AThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics+2.53%-6.62%-15.10%+65.85%+31.67%EMISEmisphere Technologies0.00%0.00%0.00%0.00%0.00%RAPTRAPT Therapeutics+6.31%+2.88%-5.20%-64.93%-50.03%TXMDTherapeuticsMD0.00%-4.26%-1.75%-4.66%-35.53%VEGPFVectura Group0.00%0.00%0.00%0.00%0.00%Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPREAprea Therapeutics3.4393 of 5 stars3.53.00.00.02.83.31.3EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ARAPTRAPT Therapeutics4.3493 of 5 stars4.32.00.03.51.72.50.6TXMDTherapeuticsMDN/AN/AN/AN/AN/AN/AN/AN/AVEGPFVectura GroupN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics3.00Buy$15.50131.69% UpsideEMISEmisphere TechnologiesN/AN/AN/AN/ARAPTRAPT Therapeutics2.50Moderate Buy$25.67185.82% UpsideTXMDTherapeuticsMD2.00HoldN/AN/AVEGPFVectura GroupN/AN/AN/AN/ACurrent Analyst RatingsLatest TXMD, EMIS, RAPT, VEGPF, and APRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$9.00 ➝ $11.003/27/2024RAPTRAPT TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.003/26/2024APREAprea TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.002/22/2024RAPTRAPT TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$61.00 ➝ $10.002/21/2024RAPTRAPT TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/21/2024RAPTRAPT TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$35.00 ➝ $13.002/21/2024RAPTRAPT TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$42.00 ➝ $10.002/21/2024RAPTRAPT TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$35.00 ➝ $15.002/21/2024RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral2/20/2024RAPTRAPT TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral2/16/2024RAPTRAPT TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$580K43.14N/AN/A$9.66 per share0.69EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/ARAPTRAPT Therapeutics$1.53M204.25N/AN/A$4.27 per share2.10TXMDTherapeuticsMD$69.96M0.35N/AN/A$3.73 per share0.61VEGPFVectura Group$244.76M4.37$0.28 per share6.33$1.16 per share1.53Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$112.66M-$3.99N/AN/AN/AN/A-61.06%-49.57%5/20/2024 (Estimated)EMISEmisphere TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/ARAPTRAPT Therapeutics-$116.80M-$3.04N/AN/AN/AN/A-63.14%-55.48%5/9/2024 (Estimated)TXMDTherapeuticsMD$112MN/A0.00∞N/A47.29%133.83%66.54%4/5/2024 (Estimated)VEGPFVectura Group$157.16M$0.266.8117.70N/AN/AN/AN/AN/ALatest TXMD, EMIS, RAPT, VEGPF, and APRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023RAPTRAPT Therapeutics-$0.85-$0.80+$0.05-$0.80N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AN/AN/ARAPTRAPT TherapeuticsN/AN/AN/AN/AN/ATXMDTherapeuticsMDN/AN/AN/AN/AN/AVEGPFVectura GroupN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A6.156.15EMISEmisphere TechnologiesN/AN/AN/ARAPTRAPT TherapeuticsN/A7.417.41TXMDTherapeuticsMDN/A1.201.20VEGPFVectura GroupN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%EMISEmisphere TechnologiesN/ARAPTRAPT Therapeutics99.09%TXMDTherapeuticsMD30.74%VEGPFVectura GroupN/AInsider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics20.90%EMISEmisphere Technologies72.90%RAPTRAPT Therapeutics5.50%TXMDTherapeuticsMD1.20%VEGPFVectura GroupN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics93.74 million2.96 millionNo DataEMISEmisphere Technologies6N/AN/ANot OptionableRAPTRAPT Therapeutics13134.80 million32.88 millionOptionableTXMDTherapeuticsMD110.58 million10.45 millionOptionableVEGPFVectura Group502604.26 millionN/ANot OptionableTXMD, EMIS, RAPT, VEGPF, and APRE HeadlinesSourceHeadlineEuropean Stocks See Mixed Session as U.K.'s FTSE Leadsthestreet.com - January 16 at 11:20 PMVECTURA GROUP LS -,000271 (V4TA.BE)finance.yahoo.com - January 15 at 2:59 PMVectura Group PLC (V4TA.BE)finance.yahoo.com - January 9 at 10:12 AMResults for 'Vectura-Fertin Pharma'afaqs.com - October 11 at 7:33 PMVectura Group (OTC:VEGPF), Short Interest Reportbenzinga.com - July 18 at 11:14 PMCarlyle stays in race for Vecturauk.finance.yahoo.com - August 27 at 12:54 PMForm 8.3 - Form-8.3 - VECTURA GROUP PLC - 20210826finance.yahoo.com - August 27 at 6:38 AMPhilip Morris chief attacks critics as Vectura bid tests investorsuk.finance.yahoo.com - August 20 at 2:24 AMMarkets: FTSE inches to new post-pandemic high as Vectura takeover draws closeruk.finance.yahoo.com - August 13 at 4:18 AMVectura auction called off after Carlyle declines to beat Philip Morris biduk.finance.yahoo.com - August 10 at 3:02 PMUPDATE 1-Vectura takeover battle could slip into auction - UK regulatorfinance.yahoo.com - August 9 at 8:04 AMPhilip Morris, Carlyle could fight it out for UK's Vectura in auction ringca.finance.yahoo.com - August 9 at 8:04 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks Your Comprehensive Guide to Investing in Bank StocksMarch 1, 2024 10:41 AMView Your Comprehensive Guide to Investing in Bank StocksCathie Wood Likes UiPath Stock Over NVDA, Should You?March 5, 2024 7:00 AMView Cathie Wood Likes UiPath Stock Over NVDA, Should You?Semis, Nvidia Set for Big Moves as GTC Conference Kicks OffMarch 18, 2024 9:10 AMView Semis, Nvidia Set for Big Moves as GTC Conference Kicks OffAll Headlines Company DescriptionsAprea TherapeuticsNASDAQ:APREAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Emisphere TechnologiesOTCMKTS:EMISEmisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.RAPT TherapeuticsNASDAQ:RAPTRAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanyTherapeuticsMDNASDAQ:TXMDTherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.Vectura GroupOTCMKTS:VEGPFVectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.